Research programme: diacylglycerol transferase-1 inhibitors - Madrigal Pharmaceuticals

Drug Profile

Research programme: diacylglycerol transferase-1 inhibitors - Madrigal Pharmaceuticals

Alternative Names: DGAT1 inhibitors - Madrigal Pharmaceuticals; RO-5131723

Latest Information Update: 30 Mar 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Roche
  • Developer Madrigal Pharmaceuticals; Roche
  • Class Carboxylic acids
  • Mechanism of Action Diacylglycerol O acyltransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Obesity; Type 2 diabetes mellitus

Most Recent Events

  • 26 Mar 2012 Preclinical trials in Obesity in USA (PO)
  • 26 Mar 2012 Preclinical pharmacodynamics data in Obesity presented at the 243rd American Chemical Society National Meeting (243rd-ACS-2012)
  • 02 Feb 2012 Preclinical trials in Type-2 diabetes mellitus in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top